Barely Significant
← all excerpts

Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.

J Immunother Cancer · 2021 · PMC7831745 · PMID 33483342

Europe PMCDOI
1
hedged sentence
0.0001
closest p · 0.0× alpha
0.0001
boldest claim

The sentences

a significant trendp=0.0001actually significant
Among the four primary tumor types described, we observed a significant trend toward improved cPFS with anti-PD1+anti-CTLA4 ICI versus anti-PD1 alone in mucosal melanoma (p=0.0001, figure 4C ).

also in 9,775 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.